



# Acotibien

Acotiamide Hydrochloride Hydrate 100 mg & 300 mg SR Tablets



Acotiamide Hydrochloride Hydrate 100 mg & 300 mg SR Tablets

# **BACKGROUND:**


Functional dyspepsia (FD) is a chronic disorder of sensation and movement (peristalsis) in the upper digestive tract. According to ROME III criteria, FD is defined as the presence of symptoms originated in the Gastro-duodenal region (i.e Postprandial Fullness, Early Satiation, Epigastric Pain and Burning)<sup>1</sup>

The prevalence of dyspepsia varies considerably between different populations. FD prevalence rates of 30.4% are seen in India.<sup>2</sup>

#### **ACOTIAMIDE IN ACOTIBIEN:**

It is a prokinetic agent, which enhances Acetylcholine (ACh) release by acting as an antagonist of  $M_1$  and  $M_2$  Muscarinic receptor and inhibits the acetylcholinesterase activity.<sup>3</sup>

It enhances electrically stimulated contractions and the release of Ach in the gastric antrum, thus facilitates motility and contraction of stomach in patients with Functional Dyspepsia.<sup>3</sup>





# **CLINICAL EVIDENCE:**

Efficacy and Safety of Orally Administered Acotiamide Extended-Release Tablets Among Functional Dyspepsia-Postprandial Distress Syndrome Patients: A Randomized, Double-Blind, Multicentre Study:


Patients: 219 Patients | Duration: 4 Weeks

#### DOSAGE:

**Test Group:** Acotiamide ER 300 mg and placebo 100 mg in the morning and placebo 100 mg in the evening and night before meal.

**Reference Group :** Acotiamide 100 mg and placebo 300 mg in the morning and Acotiamide 100 mg in the evening and night before meal.

## **RESULT:**



Both the formulations of acotiamide significantly improved symptom severity and eliminated meal-related symptoms in patients with FD

#### **CONCLUSION:**

The efficacy and safety of acotiamide ER 300 mg once daily were observed to be comparable to acotiamide immediate release 100 mg thrice daily. A significant improvement in QoL over a four-week treatment period in FD-PDS patients was observed.



Acotiamide Hydrochloride Hydrate 100 mg & 300 mg SR Tablets

## **DESCRIPTION:**

Acotibien contains Acotiamide hydrochloride hydrate and available as 100 mg and 300 mg sustained release tablets.

Acotiamide, is the world's first-in-class, prokinetic drug and world's first approved treatment for postprandial distress syndrome (PDS) symptoms of functional dyspepsia (FD).<sup>4</sup>

## **INDICATIONS:**

In Functional Dyspepsia

♦ Postprandial Fullness ♦ Epigastric Pain & Early Satiety ♦ Bloating after Meals

#### **KEY FEATURES:**

♦ Increases gastric motility ♦ Increases gastric contractions ♦ Fewer side effects

#### **MECHANISM OF ACTION:**

Acotiamide is a novel gastroprokinetic drug that exerts its activity via muscarinic receptor inhibition, which results in enhanced acetylcholine release and via inhibition of acetylcholinestrase activity in the stomach.

#### DOSAGE:

# Acotibien-100:

Acotibien 100 mg TID before meals or as prescribed by healthcare professionals.

# Acotibien-300:

Acotibien 300 mg SR once a daily before meals or as prescribed by healthcare professionals

#### References

1. Digestion; 84: 261-268: 2011 | 2. SUPPLEMENT TO JAPI • MARCH 2012 • VOL. 60 | 3. Clinical and Experimental Gastroenterology; 9: 2016 | 4. DOI: 10.7759/cureus.14361

#### La Renon Healthcare Private Limited

©2022 All rights reserved, La Renon Healthcare Private Limited